Pelthos Therapeutics (NYSEAMERICAN:PTHS) Announces Earnings Results

Pelthos Therapeutics (NYSEAMERICAN:PTHS) released its quarterly earnings data on Thursday. The company reported ($2.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.83) by $0.79, FiscalAI reports. The business had revenue of $15.39 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• Zelsuvmi generated $15.2 million in Q3 net revenue, up 114% year over year, with prescriptions rising 365% year over year and more than 10,000 HCPs prescribing to date. The company also reported new coverage agreements expanding commercial formulary access to 127 million lives, though revenue edged down from $15.4 million in Q2.
• Zelsuvmi’s gross-to-net rate increased to 31.5% in Q3 from 29.6% in Q2, partly reflecting the new PBM contract; management expects it to reach the mid-30% range as coverage expands. Executives expect the access investment to support future growth, but its revenue benefit may take multiple quarters to emerge.
• Pelthos is building launch inventory for Xepi and expects to begin promotion by the end of Q1 2027; it expects to launch XEGLYZE by the end of Q3 2027. Management expects both products to leverage its existing commercial infrastructure, although Xepi will compete with inexpensive generic treatments.
• The planned Castle Creek Biosciences transaction would add D-Fi, an investigational cell therapy for dystrophic epidermolysis bullosa, with Pelthos expecting to continue Phase III development after closing, anticipated in Q1 2027. Management sees strategic and commercial potential, but D-Fi remains unapproved and its differentiation and clinical benefit have yet to be established in Phase III.
• Pelthos ended Q3 with $17.7 million in cash and reported a $7.9 million net loss; it borrowed an additional $10 million under its Horizon facility after quarter-end. Management said projected cash flows and funding provide flexibility to advance its plans, while another potential $10 million borrowing is conditional on lender discretion and specified requirements.

Pelthos Therapeutics Stock Performance

NYSEAMERICAN:PTHS traded up $0.18 on Friday, hitting $8.21. The stock had a trading volume of 16,569 shares, compared to its average volume of 34,444. The business’s 50-day simple moving average is $18.50 and its two-hundred day simple moving average is $23.54. The stock has a market cap of $31.44 million, a price-to-earnings ratio of -0.38 and a beta of 3.41. Pelthos Therapeutics has a 52-week low of $7.77 and a 52-week high of $35.00. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40.

Hedge Funds Weigh In On Pelthos Therapeutics

A hedge fund recently raised its position in Pelthos Therapeutics stock. Pale Fire Capital SE increased its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,919 shares of the company’s stock after buying an additional 4,819 shares during the quarter. Pale Fire Capital SE owned 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent reporting period. Institutional investors own 77.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 4th. Oppenheimer cut their target price on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research note on Friday, August 14th. Alliance Global Partners reiterated a “buy” rating on shares of Pelthos Therapeutics in a report on Monday, October 26th. Lake Street Capital decreased their target price on Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Finally, Piper Sandler restated an “overweight” rating on shares of Pelthos Therapeutics in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Pelthos Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $52.83.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).